Cytokinetics (NASDAQ:CYTK) Stock Rating Lowered by Wall Street Zen

Cytokinetics (NASDAQ:CYTK) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

CYTK has been the topic of several other reports. HC Wainwright lifted their price target on shares of Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Morgan Stanley raised their price objective on Cytokinetics from $90.00 to $103.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Friday. Wells Fargo & Company lifted their target price on Cytokinetics from $95.00 to $105.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Finally, Stifel Nicolaus upped their target price on Cytokinetics from $98.00 to $108.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $100.85.

Cytokinetics Stock Performance

NASDAQ CYTK opened at $76.76 on Friday. Cytokinetics has a 52 week low of $32.89 and a 52 week high of $88.31. The stock’s 50 day moving average price is $78.91 and its two-hundred day moving average price is $70.96. The stock has a market capitalization of $9.55 billion, a price-to-earnings ratio of -10.63 and a beta of 0.39.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. Cytokinetics’s revenue for the quarter was down 57.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.12) earnings per share. On average, equities research analysts forecast that Cytokinetics will post -6.2 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Andrew Callos sold 14,000 shares of the company’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $79.88, for a total value of $1,118,320.00. Following the transaction, the executive vice president owned 58,555 shares in the company, valued at approximately $4,677,373.40. This represents a 19.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Ibraham Malik sold 3,500 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The shares were sold at an average price of $80.59, for a total value of $282,065.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares in the company, valued at $12,402,962.18. The trade was a 2.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 115,179 shares of company stock worth $9,126,054 in the last quarter. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Cytokinetics

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can boosted its holdings in Cytokinetics by 1.2% in the fourth quarter. Bank of Montreal Can now owns 13,292 shares of the biopharmaceutical company’s stock valued at $845,000 after acquiring an additional 160 shares in the last quarter. Kennedy Capital Management LLC increased its position in Cytokinetics by 1.2% during the 4th quarter. Kennedy Capital Management LLC now owns 13,183 shares of the biopharmaceutical company’s stock valued at $838,000 after purchasing an additional 162 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Cytokinetics by 46.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 171 shares in the last quarter. Vident Advisory LLC raised its holdings in Cytokinetics by 1.4% in the 4th quarter. Vident Advisory LLC now owns 16,455 shares of the biopharmaceutical company’s stock worth $1,046,000 after purchasing an additional 234 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Cytokinetics by 6.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 3,723 shares of the biopharmaceutical company’s stock worth $237,000 after purchasing an additional 239 shares during the period.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.